Kelley Jenkins
Nurse Practitioner · Springfield, MONPI 1275896326
Payments from drug & device makers
Across 245 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$719
- Novo Nordisk$588
- Lilly USA, LLC$449
- Dexcom, Inc.$415
- Amgen$266
- Bayer$218
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,409100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 41 | $719 |
| Novo Nordisk | 34 | $588 |
| Lilly USA, LLC | 23 | $449 |
| Dexcom, Inc. | 39 | $415 |
| Amgen | 21 | $266 |
| Bayer | 8 | $218 |
| Radius Health, Inc. | 8 | $202 |
| Recordati_rare_diseases_inc. | 7 | $167 |
| Globus Medical | 4 | $149 |
| Insulet Corporation | 5 | $122 |
| Chiesi USA, Inc. | 5 | $106 |
| Boehringer Ingelheim | 6 | $99 |
| Antares Pharma, Inc. | 6 | $94 |
| Pfizer | 5 | $86 |
| Averitas Pharma Inc. | 4 | $86 |
| Novartis | 5 | $82 |
| Cequr Corporation | 2 | $81 |
| AstraZeneca | 2 | $76 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 2 | $60 |
| BETA Bionics, Inc. | 2 | $44 |
| AbbVie | 2 | $30 |
| Corcept Therapeutics | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Intuity Medical Inc | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Halozyme Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
How this compares
$4,409 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 645 | $784,157 |
| JardianceEmpagliflozin | 509 | $419,240 |
| MounjaroTirzepatide | 207 | $255,633 |
| FarxigaDapagliflozin Propanediol | 252 | $189,394 |
| Tresiba Flextouch U-200Insulin Degludec | 133 | $178,213 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 162 | $170,674 |
| TrulicityDulaglutide | 138 | $160,559 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 51 | $138,048 |
| Novolog FlexpenInsulin Aspart | 250 | $69,397 |
| Repatha SureclickEvolocumab | 62 | $66,333 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 66 | $65,629 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $48,359 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 160 | $46,336 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 269 | $40,358 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $35,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $588 | $821,249716 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30 | $449 | $432,159418 claims |
| Boehringer IngelheimJardiance | $99 | $419,240509 claims |
| AstraZenecaFarxiga | $76 | $189,394252 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $60 | $65,62966 claims |
| Alvogen IncTeriparatide | $23 | $29,62011 claims |
| AbbVieSynthroid | $30 | $5,49075 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $4,611528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Springfield
- Michelle DickensSpringfield$59K
- Sara HillSpringfield$9K
- Lisa PotthoffSpringfield$9K
- Edrie WichernSpringfield$9K
- Leslie LeeSpringfield$8K
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.